Tim van Hauwermeiren
Founder bij ARGENX SE
Vermogen: 36 M $ op 31-03-2024
Profiel
Tim van Hauwermeiren, oprichter van argenx SE, is momenteel Voorzitter van Aelin Therapeutics NV en Chief Executive Officer & Executive Director bij argenx SE. Hij zit ook in de raad van bestuur van iTeos Therapeutics SA en iTeos Therapeutics, Inc. In het verleden bekleedde hij de functie van Group Head bij Procter & Gamble Co. en Senior Manager-Business Development bij Ablynx NV. Hij behaalde een MBA aan de Vlerick Leuven Gent Management School en een graduaat en een bachelor aan de Universiteit Gent.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
ARGEN-X SE
0.12% | 20-02-2024 | 71 986 ( 0.12% ) | 28 M $ | 31-03-2024 |
ARGENX SE ADR
0.03% | 31-08-2023 | 18 100 ( 0.03% ) | 7 M $ | 31-03-2024 |
ITEOS THERAPEUTICS, INC.
-.--% | 13-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Tim van Hauwermeiren
Bedrijven | Functie | Begin |
---|---|---|
ARGENX SE | Founder | 01-01-2008 |
ITEOS THERAPEUTICS, INC. | Director/Board Member | 01-06-2018 |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Director/Board Member | 27-06-2018 |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Chairman | - |
Eerdere bekende functies van Tim van Hauwermeiren
Bedrijven | Functie | Einde |
---|---|---|
RAYZEBIO, INC. | Director/Board Member | 26-02-2024 |
ABLYNX | Corporate Officer/Principal | - |
PROCTER & GAMBLE COMPANY | Corporate Officer/Principal | - |
Opleiding van Tim van Hauwermeiren
Ghent University | Graduate Degree |
Vlerick Leuven Gent Management School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
ARGENX SE | Health Technology |
ITEOS THERAPEUTICS, INC. | Health Technology |
RAYZEBIO, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Ablynx NV
Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Health Technology |